Skip to main content

Abiomed, Inc. (ABMD)

NASDAQ: ABMD · IEX Real-Time Price · USD
352.18 2.50 (0.71%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap15.98B
Revenue (ttm)935.26M
Net Income (ttm)154.41M
Shares Out45.31M
EPS (ttm)3.38
PE Ratio104.13
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume113,834
Open349.45
Previous Close349.68
Day's Range346.24 - 353.77
52-Week Range242.73 - 387.40
Beta1.35
AnalystsBuy
Price Target387.33 (+10.0%)
Est. Earnings DateOct 28, 2021

About ABMD

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous ...

IndustryHealth Care Equipment & Supplies
IPO DateJul 29, 1987
CEOMichael Minogue
Employees1,725
Stock ExchangeNASDAQ
Ticker SymbolABMD
Full Company Profile

Financial Performance

In 2020, Abiomed's revenue was $847.52 million, an increase of 0.79% compared to the previous year's $840.88 million. Earnings were $225.53 million, an increase of 11.09%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for Abiomed stock is "Buy." The 12-month stock price forecast is 387.33, which is an increase of 9.98% from the latest price.

Price Target
$387.33
(9.98% upside)
Analyst Consensus: Buy

News

Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q2 sales.

23 hours ago - Zacks Investment Research

Earnings Preview: Abiomed (ABMD) Q2 Earnings Expected to Decline

Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 day ago - Zacks Investment Research

Abiomed Second Quarter Fiscal 2022 Earnings and Conference Call Notification

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed second quarter fiscal 2022 earnings and conference call notification.

2 weeks ago - Business Wire

Abiomed (ABMD) Stock Jumps 5.9%: Will It Continue to Soar?

Abiomed (ABMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

2 weeks ago - Zacks Investment Research

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.

1 month ago - Zacks Investment Research

2 Hot Stocks to Buy and Hold Until You Retire

They have strong products and high financial performance.

Other symbols:ALGN
1 month ago - The Motley Fool

Abiomed (ABMD) Up 6% Since Last Earnings Report: Can It Continue?

Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Abiomed's (ABMD) Impella ECP Gets FDA's Breakthrough Device Tag

Abiomed's (ABMD) Impella ECP is likely to offer critical hemodynamic support to a wider pool of coronary artery disease patients.

2 months ago - Zacks Investment Research

Smallest Heart Pump From Abiomed Gets FDA Breakthrough Device Tag

The FDA has granted breakthrough device designation to Abiomed Inc's (NASDAQ: ABMD) Impella ECP expandable percutaneous heart pump. Abiomed designed the Impella ECP heart pump to be compatible with smal...

2 months ago - Benzinga

FDA Grants Breakthrough Device Designation to Impella ECP, the World's Smallest Heart Pump

DANVERS, Mass.--(BUSINESS WIRE)--The U.S. Food and Drug Administration has granted breakthrough device designation to Abiomed's Impella ECP expandable percutaneous heart pump.

2 months ago - Business Wire

Here's Why You Should Retain Abiomed (ABMD) Stock for Now

Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.

2 months ago - Zacks Investment Research

Abiomed's (ABMD) Q1 Earnings and Revenues Beat, Margins Up

Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.

2 months ago - Zacks Investment Research

Abiomed (ABMD) Beats Q1 Earnings and Revenue Estimates

Abiomed (ABMD) delivered earnings and revenue surprises of 3.77% and 3.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Abiomed Announces Record Revenue of $253 Million, Up 53% Year Over Year

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces record revenue of $253 million, up 53% year over year.

2 months ago - Business Wire

Abiomed (ABMD) Reports Next Week: Wall Street Expects Earnings Growth

Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q1 sales.

2 months ago - Zacks Investment Research

Abiomed First Quarter Fiscal 2022 Earnings and Conference Call Notification

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to release financial results for the first quarter of the fiscal year 2022 on Thursday, August 5, 2021.

3 months ago - Business Wire

Could This Recently IPOed Medical Device Maker Make You Rich?

Small-cap epilepsy treatment specialist NeuroPace looks a lot like Abiomed did in its early days.

Other symbols:NPCE
3 months ago - The Motley Fool

Abiomed's (ABMD) Impella RP With SmartAssist Gets FDA Nod

Abiomed's (ABMD) Impella RP with SmartAssist gets the highest level of approval from the FDA for treatment of right heart failure.

3 months ago - Zacks Investment Research

FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed's (NASDAQ: ABMD) newest right heart pump, the Impella RP with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) as safe...

3 months ago - Business Wire

Abiomed (ABMD) Enters Overbought Territory

Abiomed (ABMD) has moved higher as of late, but there could definitely be trouble on the horizon for this company

4 months ago - Zacks Investment Research

Abiomed's (ABMD) preCARDIA Buyout Expands Its Product Portfolio

Abiomed's (ABMD) latest acquisition is expected to improve patient outcome as well as lower the cost of care.

4 months ago - Zacks Investment Research

Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed's product portfolio to expand options for ...

4 months ago - Business Wire

Here's Why Abiomed Stock Is Attractive After A 20% Drop

The stock price of Abiomed , a medical devices company best known for Impella, the world's smallest heart pump, looks attractive at current levels of $280, despite it being up 2x from the levels of $132...

4 months ago - Forbes

Abiomed to Present at Upcoming Investor Conferences

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at William Blair's 41st Annual Growth Stock Conference and the Jefferies Virtual Healthcare Conference.

4 months ago - Business Wire